| Size & multiples | |||
| Market Cap | ₩4.03T | Enterprise Value | ₩4.25T |
| P/E (TTM) | — | PEG (trailing) | — |
| P/S | 47.85× | P/FCF | — |
| EV/EBITDA | — | EV/EBIT | — |
| EV/Sales | 50.51× | EV/FCF | — |
| FCF Yield | −2.72% | Buyback Yield | — |
| Owner Earnings Yield | — | Shareholder Yield | — |
| Cost of capital & EVAmethodology → | |||
| Beta (5y monthly) | 0.91 | Risk-free (assumed) | 4.00% |
| Equity risk premium (assumed) | 5.00% | Cost of Equity | 8.56% |
| After-tax Cost of Debt | — | WACC | — |
| ROIC | −11.58% | EVA Spread (ROIC−WACC) | — |
| EVA | — | ||
Flows TTM (last 4 quarters); latest annual for: EPS (Diluted) · EPS TTM -₩1680.00 · revenue TTM ₩84.17B · FCF TTM -₩109.53B (in KRW)
Output of a disclosed model whose assumptions may be wrong — research information, not investment advice. See the Disclaimer.
Compared against all 1054 Health Care names we cover — one sector-wide pool, so the median skews toward smaller (often unprofitable) companies. Try the Size band for a cap-matched read.
| Metric | This (FY) | Peer median | IQR (25–75) | %ile |
|---|---|---|---|---|
| FCF Yield | -2.7% | -7.9% | -35.6%–1.4% | 62 ↑strong |
| Dividend Yield | 0.0% | 1.1% | 0.2%–2.4% | 10 ↓weak |
| Net Margin | -262.0% | -21.2% | -325.3%–7.2% | 28 ↓weak |
| Operating Margin | -123.8% | -34.5% | -552.0%–8.0% | 38 ↓weak |
| ROE | -44.3% | -36.8% | -92.5%–4.5% | 45 ↓weak |
